



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 17.07.2021

To
National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400 051

Subject: Reply to clarification sought- NSE E-mail dated 15.07.2021

Dear Sir/Ma'am

This refers to your E-mail dated 15th July, 2021 through which your good office have sought clarification with respect to format of submission of financial results.

We wish to clarify that UDIN has got inadvertently missed out from the Independent Auditors Report on both Standalone and Consolidated basis for the financial year 31st March, 2021.

Enclosing herewith revised copy of financial results for the financial year ended 31st March 2021.

This is for the information of Exchange and stakeholders.

Thanking You
Yours Sincerely
for Parenteral Drugs (India) Limited


Suruchi Maheshwari
Company Secretary



PARENTERAL DRUGS (INDIA) LIMITED


Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2021

(Rs in Lakh, unless otherwise stated)						
Sr. No.	Particulars	Quarter Ended 31-03-2021 (Audited)	Quarter Ended 31-12-2020 (Unaudited)	Quarter Ended 31-03-2020 (Audited)	Year Ended 31-03-2021 (Audited)	Year Ended 31-03-2020 (Audited)
	Refer Notes below					
	Income					
I	(a) Revenue From Operation (Including excise duty)	256.99	203.73	857.74	1,216.75	3,187.48
II	(b) Other Operating Income	2.66	1.16	21.01	6.38	25.18
III	Total Income (I+II)	259.65	204.89	878.75	1,223.13	3,212.66
IV	Expenditure					
	Cost of Material Consumed	70.94	149.23	80.92	592.80	518.40
	Purchase of Stock In Trade	35.09	-	-	35.09	-
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	20.65	(110.19)	3.03	(61.54)	113.70
	Employee Benefit Expenses	153.92	369.18	542.06	1,451.18	1,920.56
	Finance costs	3,246.01	3,209.09	2,871.99	12,543.61	10,995.57
	Depreciation, Amortisation and Impairment Expenses	431.71	433.65	431.67	1,732.65	1,734.59
	Other Expenditure	(362.81)	82.56	640.52	376.38	2,103.17
	Total Expenses (IV)	3,595.51	4,133.52	4,570.19	16,670.17	17,385.99
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(3,335.86)	(3,928.63)	(3,691.44)	(15,447.04)	(14,173.33)
VI	Exceptional items	-	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	(3,335.86)	(3,928.63)	(3,691.44)	(15,447.04)	(14,173.33)
VIII	Tax Expenses					
	(1) Current Tax					
	(2) Deferred Tax	(851.47)	(831.17)	(498.21)	(3,275.90)	(2,766.34)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,484.39)	(3,097.46)	(3,193.23)	(12,171.14)	(11,406.99)
X	Net Profit / (Loss) for the period from discontinuing operations					
XI	Tax expense of discontinuing operations					
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)					
XIII	Profit/(loss) for the period (IX+XII)	(2,484.39)	(3,097.46)	(3,193.23)	(12,171.14)	(11,406.99)
XIV	Other Comprehensive Income					
	A (i) Item that will not be reclassified to Profit or loss	31.69	(5.29)	(28.61)	14.19	(31.20)
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss					
	B (i) Item that will be reclassified to Profit or loss					
	(ii) Income tax relation to Item that will be reclassified to Profit or loss					
XV	Total comprehensive Income for the period (XIII+XIV) (comprising profit (loss) and other comprehensive income for the period)	(2,452.70)	(3,102.75)	(3,221.84)	(12,156.95)	(11,438.19)
XVI	Paid Up Equity share capital (Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation):					
	(a) Basic (In Rs)	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)
	(b) Diluted (In Rs)	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)
XVIII	Earnings per share (for discontinued operation):					
	(a) Basic (In Rs)	-	-	-	-	-
	(b) Diluted (In Rs)	-	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation):					
	(a) Basic (In Rs)	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)
	(b) Diluted (In Rs)	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ N150809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED


Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- 1 The above audited standalone financial results of the Company have been reviewed by the Audit Committee and approved by Board of Directors at their respective meeting held on 30-06-2021
- 2 The above standalone financial results for the quarter and year ended 31 st March 2021 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017.
- 3 The figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.
- 4 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- 5 The previous period figures have been regrouped/rearranged wherever found necessary.
- 6 The audited standalone financial results of the Company are available on the web site of the Company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Govind Das Garg
Whole Director
DIN : 00520067




Place: Indore
Date: 30.06.2021

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register




PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Audited Standalone Statement of Assets and Liabilities:

Sr. No.	Particulars	(Rs in Lakh)	
		As at 31-03-21 (Audited)	As at 31-03-20 (Unaudited)
I.	ASSETS		
(1)	Non-current assets		
	(a) Property, plant and equipment		
	(b) Intangible assets	32,181.41	33,914.07
	(b) Intangible assets	-	-
	(i) Investments	1.00	1.00
	(ii) Loans	257.85	257.85
	(ii) Others	297.88	278.93
	(d) Other non-current assets	-	-
	(e) Deferred tax Assets(Net)	624.20	607.05
	Total Non-current assets	16,583.08	13,312.17
		49,944.42	48,370.07
(2)	Current assets		
	(a) Inventories		
	(b) Financial Assets	159.10	125.54
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Cash and cash equivalents	-	-
	(iv) Bank balances ther than (iii) above	5.70	10.72
	(v) Loans	-	-
	(c) Other Current Assets	882.04	846.74
		5,687.90	5,690.87
	Total Current assets	6,734.74	6,673.87
	Total Assets	56,679.16	55,043.94
II.	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital		
	(b) Other Equity	2,981.63	2,981.63
	Total Equity	(71,301.67)	(59,144.71)
		(68,320.04)	(56,163.08)
	LIABILITIES		
(1)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings		
	(ii) Other financial liabilities	10,623.51	10,623.51
	(b) Other non-current liabilities	-	-
	Total Non-Current Liabilities	12.00	13.50
		10,635.51	10,637.01
(2)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings		
	(ii) Trade payables	781.07	792.98
	(iii) Other financial liabilities	104,113.43	91,570.14
	(b) Other current liabilities		
	(c) Provisions	8,438.12	7,261.31
		1,031.07	945.58
	Total Current liabilities	114,363.69	100,570.01
	Tota Equity and Liabilities	56,679.16	55,043.94

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



JAS-ANZ
www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Audited Standalone Statement of Cash flow for the Year ended 31st March 2021

Particulars	(Rs.in Lakh)	
	For the year ended March 31, 2021 (Audited)	For the year ended March 31, 2020 (Audited)
Cash flow from operating activities		
Profit/(Loss) before tax		
Adjustments to reconcile profit before tax to net cash used in operating activities	(15,447.04)	(14,173.33)
Depreciation and impairment of property, plant and equipment	-	-
Remeasure of the defined benefit plans	1,732.65	1,734.59
Equity Instruments directly taken to OCI	19.17	(42.16)
Finance income	-	-
Finance costs	(6.19)	(7.89)
Provision for Gratuity and compensated absences	12,543.61	10,995.57
Operating profit before working capital changes	85.49	107.91
Working capital adjustments	(1,072.31)	(1,385.32)
(Increase)/ Decrease in inventories	-	-
(Increase)/ Decrease in trade and other receivables	(33.56)	271.52
(Increase)/ Decrease in other assets	-	-
(Increase)/ Decrease in Other Balance with Banks	(14.17)	(32.69)
Decrease/(Increase) in Long-term loans & advances	-	35.10
Increase/ (Decrease) in trade and other payables	(54.26)	(358.18)
Increase/ (Decrease) in other liabilities	(11.91)	(393.99)
Cash generated from operations	13,718.60	13,100.09
Income Tax paid	12,532.39	11,236.52
Net cash flows from operating activities	12,532.39	11,236.52
Cash flow from investing activities		
Payment for purchase and construction of property, plant and equipment	-	-
Purchase of Investments	-	-
Interest received	6.19	7.89
Net cash flows from investing activities	6.19	7.89
Cash flow from financing activities		
Proceeds from issue of share capital	-	-
Increase/(decrease) in Short Term Borrowings	-	-
Increase/(decrease) in Long Term Borrowings	-	(247.55)
Finance cost	(12,543.61)	(10,995.57)
Net cash flows from financing activities	(12,543.61)	(11,243.11)
Net increase / (decrease) in cash and cash equivalents	(5.03)	1.29
Cash and cash equivalents at the beginning of the year	10.72	9.43
Effect of exchanges rate changes on cash and cash equivalents	-	-
Cash and cash equivalents at the end of the year	5.69	10.72
Reconciliation of Cash and Cash equivalents with the Balance Sheet		
Cash and Bank Balances as per Balance Sheet (Note 9b)		
Cash on hand	-	-
Bank balances	0.03	0.05
Cash and Cash equivalents as restated as at the year end	5.66	10.67
	5.69	10.72




Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register

Independent Auditor's Report on Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF PARENTERAL DRUGS (INDIA) LIMITED

Opinion

We have audited the accompanying standalone quarterly financial results of Parenteral Drug (India) Limited (the company) for the quarter ended 31st March 2021 and the year to date results for the period from 1st April, 2020 to 31st March, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

i. Our presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with relevant SEBI Circulars issued from time to time in this regard; and

ii. give a true and fair view in conformity with there cognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarter ended 31st March, 2021 as well as the year to date results for the period from 01st April, 2020 to 31st March, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net loss and other comprehensive income and other financial

Information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standard on Auditing, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances Under section 143 (3) (i) of the

Act, we are also responsible for expressing our opinion on whether company has in place an adequate internal financial control system over financial reporting and the operative effectiveness of such control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Singhal Jain & Co.

Chartered Accountants

Firm Regn. No. 013995C



Kamal Jain
(Partner)
M.No. 406604

Place : Jaipur

Date : 30th June 2021

UDIN :- 21406604AAAA L2295



PARENTERAL DRUGS (INDIA) LIMITED


Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;

Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED
Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2021

Sr. No.	Particulars	(Rs in Lakh, unless otherwise stated)				
		Quarter Ended 31-03-2021 (Audited)	Quarter Ended 31-12-2020 (Unaudited)	Quarter Ended 31-03-2020 (Audited)	Year Ended 31-03-2021 (Audited)	Year Ended 31-03-2020 (Audited)
I	(a) Revenue From Operation(Including excise duty)	256.99	203.73	857.74	1,216.75	3,187.48
II	(b) Other Income	2.66	1.16	21.01	6.38	25.18
III	Total Income (I+II)	259.65	204.89	878.75	1,223.13	3,212.66
IV	Expenditure					
	Cost of Material Consumed	70.94	149.23	80.92	592.80	518.40
	Purchase of Stock In Trade	35.09	-	-	35.09	-
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	20.65	(110.19)	3.03	(61.54)	113.70
	Employee Benefit Expenses	153.92	369.18	542.06	1,451.18	1,920.56
	Finance costs	3,246.06	3,209.09	2,872.04	12,543.66	10,995.62
	Depreciation and Amortisation Expenses	431.71	433.65	431.67	1,732.65	1,734.59
	Other Expenditure	(362.71)	82.56	640.70	376.48	2,103.39
	Total Expenses (IV)	3,595.66	4,133.52	4,570.42	16,670.32	17,386.26
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(3,336.01)	(3,928.63)	(3,691.67)	(15,447.19)	(14,173.60)
VI	Exceptional items	-	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	(3,336.01)	(3,928.63)	(3,691.67)	(15,447.19)	(14,173.60)
VIII	Tax Expenses					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	(851.47)	(831.17)	(498.21)	(3,275.90)	(2,766.34)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,484.54)	(3,097.46)	(3,193.46)	(12,171.29)	(11,407.26)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(2,484.54)	(3,097.46)	(3,193.46)	(12,171.29)	(11,407.26)
XIV	Other Comprehensive Income					
	A (i) Item that will not be reclassified to Profit or loss	31.69	(5.29)	(28.61)	14.19	(31.20)
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss	-	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-	-
XV	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	(2,452.85)	(3,102.75)	(3,222.07)	(12,157.10)	(11,438.46)
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation) :					
	(a) Basic	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)
	(b) Diluted	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)
XVIII	Earnings per share (for discontinued operation) :					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation) :					
	(a) Basic	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)
	(b) Diluted	(8.33)	(10.41)	(10.71)	(40.82)	(38.36)



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- The above audited consolidated results of the Company have been reviewed by the Audit Committee and approved by Board of Directors at their respective meetings held on 30-06-2021.
- Additional information on audited standalone financial results are given below:

Particulars	Rs. In Lakh				
	Quarter Ended 31-03-2021 (Audited)	Quarter Ended 31-12-2020 (Unaudited)	Quarter Ended 31-03-2020 (Audited)	Year to Ended 31-03-2021 (Audited)	Year to Ended 31-03-2020 (Audited)
Total Income from operations	259.65	204.89	878.75	1,223.13	3,212.66
Profit/Loss before tax	(3,335.86)	(3,928.63)	(3,691.44)	(15,447.04)	(14,173.33)
Profit/Loss after tax	(2,452.70)	(3,102.75)	(3,221.84)	(12,156.95)	(11,438.19)

- The above consolidated financial results for the quarter and year ended 31 st March, 2021 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017.
- The figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.
- At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- The previous period figures have been regrouped/rearranged wherever found necessary.
- The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Govind Das Garg
Whole Director
DIN 00520067




Place: Indore
Date: 30.06.2021

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register




PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Audited Consolidated Statement of Assets and Liabilities:

Sr. No.	Particulars	Rs. In Lakh	
		As at 31-03-21 Audited	As at 31-03-20 Audited
I.	ASSETS		
(1)	Non-current assets		
	(a) Property, plant and equipment	32,181.41	33,914.07
	(b) Intangible assets		
	(c) Financial Assets		
	(i) Investments	240.10	240.10
	(ii) Loans	297.87	278.93
	(ii) Others	-	-
	(d) Other non-current assets	710.60	693.28
	(e) Deferred tax Assets(Net)	16,583.09	13,312.17
	Total Non-current assets	50,013.07	48,438.55
(2)	Current assets		
	(a) Inventories	159.10	125.54
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables		
	(iii) Cash and cash equivalents	5.70	10.81
	(iv) Bank balances ther than (iii) above	-	-
	(v) Loans	939.34	904.08
	(c) Other Current Assets	5,703.15	5,706.12
	Total Current assets	6,807.29	6,746.55
	Total Assets	56,820.36	55,185.10
II.	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	2,981.63	2,981.63
	(b) Other Equity	(71,269.33)	(59,112.23)
	Total Equity	(68,287.70)	(56,130.60)
	Minority Interest	12.25	12.25
	LIABILITIES		
(1)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	10,719.92	10,719.78
	(b) Other non-current liabilities	12.00	13.50
	Total Non-Current Liabilities	10,731.92	10,733.28
(2)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	781.27	793.13
	(iii) Other financial liabilities	104,113.43	91,570.15
	(b) Other current liabilities	8,438.12	7,261.31
	(c) Provisions	1,031.07	945.58
	Total Current liabilities	114,363.89	100,570.17
	Total Equity and Liabilities	56,820.36	55,185.10



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (iv. P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Audited Consolidated Statement of Cash flows for the year ended 31st March 2021

(Rs.in Lakh)

Particulars	For the year ended March 31, 2021 (Audited)	For the year ended March 31, 2020 (Audited)
Cash flow from operating activities		
Profit/(Loss) before tax	(15,447.19)	(14,173.61)
Adjustments to reconcile profit before tax to net cash used in operations	-	-
Depreciation and impairment of property, plant and equipment	1,732.65	1,734.59
Remeasure of the defined benefit plans	19.17	(42.16)
Equity Instruments directly taken to OCI	-	-
Finance income	(6.18)	(7.89)
Finance costs	12,543.65	10,995.62
Provision for Gratuity and compensated absences	85.49	107.91
Operating profit before working capital changes	(1,072.41)	(1,385.54)
Working capital adjustments		
(Increase)/ Decrease in inventories	(33.56)	271.52
(Increase)/ Decrease in trade and other receivables	-	-
(Increase)/ Decrease in other assets	(14.34)	(33.18)
(Increase)/ Decrease in Other Balance with Banks	-	35.10
Decrease/(Increase) in Long-term loans & advances	(54.21)	(357.59)
Increase/ (Decrease) in trade and other payables	(11.86)	(394.06)
Increase/ (Decrease) in other liabilities	13,718.61	13,100.09
Cash generated from operations	12,532.23	11,236.33
Income Tax paid	-	-
Adjusted due to closure of subsidiaries	-	-
Net cash flows from operating activities	12,532.23	11,236.33
Cash flow from investing activities		
Payment for purchase and construction of property, plant and equipment	-	-
Purchase of Investments	-	-
Interest received	6.19	7.89
Net cash flows from investing activities	6.19	7.89
Cash flow from financing activities		
Proceeds from issue of share capital	-	-
Increase/(decrease) in Short Term Borrowings	-	-
Increase/(decrease) in Long Term Borrowings	0.12	(247.32)
Finance costs	(12,543.65)	(10,995.62)
Net cash flows from financing activities	(12,543.53)	(11,242.94)
Net increase / (decrease) in cash and cash equivalents	(5.11)	1.28
Cash and cash equivalents at the beginning of the year	10.81	9.53
Effect of exchanges rate changes on cash and cash equivalents	-	-
Cash and cash equivalents at the end of the year	5.70	10.81



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register

Independent Auditor's Report on Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Parenteral Drugs (India) Limited

Opinion

We have audited the accompanying consolidated annual financial results of Parenteral Drugs (India) Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31st March 2021, attached here with, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements /financial results/ financial information of the subsidiaries the aforesaid consolidated financial results:

- (i) Include the annual financial results of the following entities Parenteral Drugs (India) Limited, Parenteral Biotech Limited, Parenteral Impex Limited.
- (ii) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with other SEBI Circulars issued from time to time in this regard; and
- (iii) Give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the Group for the year ended 31st March 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group entities in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group for preventing and detecting frauds and other irregularities ;selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standard on Auditing, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with Standard of Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

We did not audit the annual financial statement / financial information of Two subsidiaries included in the statement, whose financial information reflect total assets of Rs.1,58,95,102/- as at 31st March 2021, total revenue of Rs. Nil and total net loss after tax of Rs. (14,749/-), total comprehensive loss of Rs. (14,749/-) and cash out flow net Rs.8,759/- for the year ended 31st March 2021, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements/Financial Results/financial information of these entities have been furnished to us by management, and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.



Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

The Financial Results include the results for the quarter ended 31st March 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Singhal Jain & Co.

Chartered Accountants

Firm Regn. No. 013995C



Kamal Jain
(Partner)
No. 406604

Place : Jaipur

Date : 30th June 2021

UDIN - 21406604AAAAAL2295



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 30.06.2021

To
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051

To
Bombay Stock Exchange Limited
Phiroze Jeebhoy Towers,
Rotund Bldg., Dalal Street,
Mumbai- 400051

SYMBOL: PDPL

Scrip Code: 524689

Dear Sir/Madam

Sub: Declaration pursuant to Second Proviso to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended


DECLARATION

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, I hereby declare that M/s Singhal Jain & Co., Chartered Accountants, Statutory Auditors of the Company, have issued an Audit Report with an unmodified opinion on Audited Financial Statements of the Company (both Standalone and Consolidated) for the year ended 31st March, 2021.

Kindly take the same on record.

Thanking you

for Parenteral Drugs (India) Limited


Govind Das Garg
Whole Time Director
DIN: 00520067

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register